Literature DB >> 31217862

Melatonin improves therapeutic potential of mesenchymal stem cells-derived exosomes against renal ischemia-reperfusion injury in rats.

Faisal A Alzahrani1,2,3.   

Abstract

Renal ischemia-reperfusion injury (RIRI) is one of the main causes for acute kidney injury (AKI). Many previous attempts failed to adopt a suitable treatment regimen for AKI. Recently, combined melatonin (Mel) and mesenchymal stem cell (MSC)-derived exosomes (Exo) therapy gave a promising therapeutic option for acute liver ischemic injury, however this treatment approach has not been tested against RIRI yet. This study tested the hypothesis that administration of exosomes derived from MSCs preconditioned with Mel gave best protection against RIRI as compared to therapy by MSCs or exosomes derived from non-preconditioned MSCs. Female adult rats (n = 60) equally divided into control group, sham group, RIRI group (induced by bilateral renal arteries clamping), RIRI + MSCs group (1 × 106 bone marrow derived MSCs), RIRI + Exo group (250 μg Exo derived from no-preconditioned MSCs), and RIRI + Mel + Exo group (250 μg Exo derived from Mel preconditioned MSCs). MSCs or Exo was bilaterally injected once in each renal artery during reperfusion. The obtained results revealed notable improvement in RIRI following all treatment (MSCs, Exo, and Exo + Mel) with best improvement in Exo + Mel group as evidenced by: 1) decreased kidney injury histopathological score; 2) reduced blood levels of kidney damage markers [blood urea nitrogen (BUN) and creatinine]; 3) declined oxidative stress status (MDA level, HIF1α gene, and NOX2 protein); 4) increased anti-oxidant status (HO1 gene, and SOD, CAT, GPX activities); 5) declined apoptosis (caspase 3 activity and mRNA, and PARP1, Bax genes), 6) induced anti-apoptotic effect (Bcl2 gene); 7) inhibition of inflammation (decreased MPO activity and ICAM1, IL1B, NFkB genes and increased IL10 genes); 8) improved regeneration (bFGF, HGF and SOX9 proteins); and 9) enhanced angiogenesis (VEGF gene). These data indicate that treatment with exosomes derived from MSCs preconditioned with melatonin gave best protective effect against renal ischemia-reperfusion injury as compared to therapy by non-preconditioned MSCs or their exosomes.

Entities:  

Keywords:  Melatonin; exosomes; mesenchymal stem cells; renal ischemia

Year:  2019        PMID: 31217862      PMCID: PMC6556638     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  23 in total

1.  Editorial: Extracellular Vesicles: From Characterization to Treatment.

Authors:  Xinlei Li; Jeffrey David Galley
Journal:  Front Cell Dev Biol       Date:  2022-06-17

2.  Mesenchymal Stem Cells-Derived Exosomes Ameliorate Ischemia/Reperfusion Induced Acute Kidney Injury in a Porcine Model.

Authors:  Jianni Huang; Hao Cao; Binbin Cui; Xiaoyan Ma; Ling Gao; Chao Yu; Fengchen Shen; Xinyu Yang; Na Liu; Andong Qiu; Guangyan Cai; Shougang Zhuang
Journal:  Front Cell Dev Biol       Date:  2022-05-24

3.  Melatonin-stimulated MSC-derived exosomes improve diabetic wound healing through regulating macrophage M1 and M2 polarization by targeting the PTEN/AKT pathway.

Authors:  Wei Liu; Muyu Yu; Dong Xie; Longqing Wang; Cheng Ye; Qi Zhu; Fang Liu; Lili Yang
Journal:  Stem Cell Res Ther       Date:  2020-06-29       Impact factor: 6.832

Review 4.  Preclinical Experimental Applications of miRNA Loaded BMSC Extracellular Vesicles.

Authors:  Zafer Cetin; Eyup I Saygili; Gokhan Görgisen; Emel Sokullu
Journal:  Stem Cell Rev Rep       Date:  2021-01-04       Impact factor: 5.739

Review 5.  Exosomes and Melatonin: Where Their Destinies Intersect.

Authors:  Adriana Alonso Novais; Luiz Gustavo de Almeida Chuffa; Débora Aparecida Pires de Campos Zuccari; Russel J Reiter
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

Review 6.  Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Potential Therapeutic Strategy for Acute Kidney Injury.

Authors:  Jia-Kun Li; Cheng Yang; Ying Su; Jing-Chao Luo; Ming-Hao Luo; Dan-Lei Huang; Guo-Wei Tu; Zhe Luo
Journal:  Front Immunol       Date:  2021-06-03       Impact factor: 8.786

7.  Mesenchymal Stem Cell Derived Extracellular Vesicles Ameliorate Kidney Injury in Aristolochic Acid Nephropathy.

Authors:  Sharad Kholia; Maria Beatriz Herrera Sanchez; Massimo Cedrino; Elli Papadimitriou; Marta Tapparo; Maria Chiara Deregibus; Stefania Bruno; Federica Antico; Maria Felice Brizzi; Peter J Quesenberry; Giovanni Camussi
Journal:  Front Cell Dev Biol       Date:  2020-03-24

Review 8.  Mesenchymal Stem/Stromal Cell-Derived Exosomes for Immunomodulatory Therapeutics and Skin Regeneration.

Authors:  Dae Hyun Ha; Hyun-Keun Kim; Joon Lee; Hyuck Hoon Kwon; Gyeong-Hun Park; Steve Hoseong Yang; Jae Yoon Jung; Hosung Choi; Jun Ho Lee; Sumi Sung; Yong Weon Yi; Byong Seung Cho
Journal:  Cells       Date:  2020-05-07       Impact factor: 6.600

Review 9.  Current Knowledge and Future Perspectives on Mesenchymal Stem Cell-Derived Exosomes as a New Therapeutic Agent.

Authors:  Hyeon Su Joo; Ju Hun Suh; Hyeon Ji Lee; Eun Song Bang; Jung Min Lee
Journal:  Int J Mol Sci       Date:  2020-01-22       Impact factor: 5.923

10.  Exosomes Derived From Mesenchymal Stem Cells Ameliorate Renal Ischemic-Reperfusion Injury Through Inhibiting Inflammation and Cell Apoptosis.

Authors:  Long Li; Rulin Wang; Yichen Jia; Ruiming Rong; Ming Xu; Tongyu Zhu
Journal:  Front Med (Lausanne)       Date:  2019-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.